RecruitingNCT07335679

Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex Carcinoma


Sponsor

University Hospital, Strasbourg, France

Enrollment

60 participants

Start Date

Jun 10, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Adrenal corticosteroid carcinoma (ACC) is a rare tumor of the adrenal cortex, with an estimated prevalence of 0.5 to 2 cases per million inhabitants per year. Two peaks in incidence have been described: during the first decade of life and between 40 and 50 years of age, with a slight female predominance (female-to-male ratio of 1.5). The majority of cases (\>90%) are sporadic, particularly in adults. ACC may be discovered incidentally during an imaging examination performed for another reason (10 to 20% of cases) or in connection with a tumor syndrome (40-60% of cases) or hormonal hypersecretion (40 to 74% of cases). The diagnosis of CCS can be suggested by the combination of morphological characteristics seen on imaging and clinical and biological features (secretory syndrome), but only histopathology allows for a definitive diagnosis. Furthermore, histopathology enables the assessment of aggressiveness criteria (Weiss score, Ki67), which will influence further management and prognosis. Given that CCS is a rare tumor, the investigators aim to study the clinical, biological, morphological, and histological characteristics and evaluate the prognosis of patients treated at our center in order to better understand the natural history of CCS and improve patient management.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a data registry study tracking patients treated at Strasbourg University Hospital in France who have been diagnosed with adrenocortical carcinoma (a rare cancer of the outer layer of the adrenal glands). The study collects clinical information to better understand outcomes over time. **You may be eligible if...** - You are 18 or older - You have been followed at Strasbourg University Hospital for adrenocortical carcinoma diagnosed between January 2000 and May 2025 **You may NOT be eligible if...** - Your tumor was reclassified as something other than adrenocortical carcinoma after a detailed pathology review Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Service d'Endocrinologie, Diabétologie, Nutrition - CHU de Strasbourg - France

Strasbourg, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07335679


Related Trials